Sugi Predict

Sugi Predict / Compounds / SCHEMBL893688

SCHEMBL893688

SCHEMBL893688

O=S(=O)(c1ccccc1)N1CCNCC1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.68
▸ PKM P14618 2/20 0.65
▸ POLB P06746 1/20 0.61
▸ ALDH1A1 P00352 4/20 0.58
▸ LMNA P02545 1/20 0.58
▸ HTR6 P50406 3/20 0.57
▸ DRD3 P35462 1/20 0.56
▸ CYP2C9 P11712 1/20 0.55
▸ GAA P10253 2/20 0.55
▸ CYP2D6 P10635 1/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ APOBEC3A P31941 1/20 0.53
▸ APOBEC3G Q9HC16 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17246 1.00 MAPT (0.68) MAPTPKMPOLBALDH1A1LMNA
Piperazine SCHEMBL28102264 0.98 MAPT (0.66) MAPTPKMPOLBALDH1A1LMNA
SCHEMBL15284182 0.98 MAPT (0.66) MAPTPKMPOLBALDH1A1LMNA
Hydrochloric Acid SCHEMBL16186 0.98 MAPT (0.66) MAPTPKMPOLBALDH1A1LMNA
Hydrochloric Acid SCHEMBL8130433 0.96 MAPT (0.64) MAPTPKMPOLBALDH1A1LMNA
SCHEMBL6973412 0.93 ALDH1A1 (0.60) MAPTPKMPOLBALDH1A1LMNA
SCHEMBL4225535 0.89 ALDH1A1 (0.72) MAPTPKMPOLBALDH1A1CYP2C9
SCHEMBL28897265 0.89 ALDH1A1 (0.64) MAPTPKMPOLBALDH1A1LMNA
Trifluoroacetic Acid SCHEMBL7430837 0.87 ALDH1A1 (0.55) MAPTPKMPOLBALDH1A1HTR6
SCHEMBL3830424 0.85 POLB (0.80) PKMPOLBALDH1A1LMNACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3226858-B1 IMIDAZOLE-BASED ANTIMICROBIAL AGENTS PROCOMCURE BIOTECH GMBH (AT) 2021-02-03 — — EP disclosed
US-10456379-B2 Imidazole-based antimicrobial agents PROCOMCURE BIOTECH GMBH (AT) 2019-10-29 — — US disclosed
US-10322110-B2 Imidazole-based antimicrobial agents PROCOMCURE BIOTECH GMBH (AT) 2019-06-18 — — US disclosed
US-10314820-B2 Imidazole-based heterocyclic compounds PROCOMCURE BIOTECH GMBH (AT) 2019-06-11 — — US disclosed
US-20170368032-A1 Imidazole-Based Antimicrobial Agents PROCOMCURE BIOTECH GMBH (AT) 2017-12-28 — — US disclosed
US-20170340613-A1 Novel Imidazole-Based Heterocyclic Compounds PROCOMCURE BIOTECH GMBH (AT) 2017-11-30 — — US disclosed
US-20170334887-A1 Imidazole-Based Antimicrobial Agents PROCOMCURE BIOTECH GMBH (AT) 2017-11-23 — — US disclosed
EP-3226858-A1 IMIDAZOLE-BASED ANTIMICROBIAL AGENTS Procomcure Biotech GmbH (AT) 2017-10-11 — — EP disclosed
WO-2016087615-A1 NOVEL IMIDAZOLE-BASED HETEROCYCLIC COMPOUNDS PROCOMCURE BIOTECH GMBH (AT) 2016-06-09 — — WO disclosed
WO-2016087616-A1 IMIDAZOLE-BASED ANTIMICROBIAL AGENTS PROCOMCURE BIOTECH GMBH (AT) 2016-06-09 — — WO disclosed
WO-2016087618-A1 IMIDAZOLE-BASED ANTIMICROBIAL AGENTS PROCOMCURE BIOTECH GMBH (AT) 2016-06-09 — — WO disclosed
US-20120108547-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2012-05-03 — — US disclosed
US-20120101065-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2012-04-26 — — US disclosed
US-20120083470-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2012-04-05 — — US disclosed
US-8067395-B2 Inhibitors of tyrosine kinases and uses thereof PHARMACYCLICS, INC. (US) 2011-11-29 — — US disclosed
US-20100035841-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2010-02-11 — — US disclosed
US-7625880-B2 Inhibitors of tyrosine kinases and uses thereof PHARMACYCLICS, INC. (US) 2009-12-01 — — US disclosed
US-20080039426-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2008-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108547-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF LCK, ABL1, SRC MAPT 2159/4885PKM 801/4885POLB 1986/4885
US-20100035841-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF LCK, ABL1, SRC MAPT 2159/4885PKM 801/4885POLB 1986/4885
US-20170334887-A1 Imidazole-Based Antimicrobial Agents TLR5, NISCH, SLC11A2 MAPT 1161/4885PKM 1470/4885POLB 1637/4885
US-10456379-B2 Imidazole-based antimicrobial agents TLR5, NISCH, SLC11A2 MAPT 1161/4885PKM 1470/4885POLB 1637/4885
US-20120083470-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF LCK, ABL1, SRC MAPT 2159/4885PKM 801/4885POLB 1986/4885
US-10322110-B2 Imidazole-based antimicrobial agents ARG1, SLC11A2, IKZF3 MAPT 4173/4885PKM 2520/4885POLB 3215/4885
US-20170368032-A1 Imidazole-Based Antimicrobial Agents TLR5, NISCH, SLC11A2 MAPT 1161/4885PKM 1470/4885POLB 1637/4885
US-20080039426-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF LCK, ABL1, SRC MAPT 2159/4885PKM 801/4885POLB 1986/4885
US-20120101065-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF LCK, ABL1, SRC MAPT 2159/4885PKM 801/4885POLB 1986/4885
US-20170340613-A1 Novel Imidazole-Based Heterocyclic Compounds SLC11A2, MIF, NISCH MAPT 2113/4885PKM 497/4885POLB 2166/4885
US-10314820-B2 Imidazole-based heterocyclic compounds MIF, SLC11A2, TLR5 MAPT 1610/4885PKM 381/4885POLB 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.